GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Margin of Safety % (DCF Earnings Based)

LLY (Eli Lilly and Co) Margin of Safety % (DCF Earnings Based) : -235.33% (As of Mar. 05, 2025)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2025-03-05), Eli Lilly and Co's Predictability Rank is 3.5-Stars. Eli Lilly and Co's intrinsic value calculated from the Discounted Earnings model is $271.69 and current share price is $911.06. Consequently,

Eli Lilly and Co's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is -235.33%.

Competitive Comparison of Eli Lilly and Co's Margin of Safety % (DCF Earnings Based)

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co's Margin of Safety % (DCF Earnings Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Margin of Safety % (DCF Earnings Based) falls into.


Eli Lilly and Co Margin of Safety % (DCF Earnings Based) Calculation

Eli Lilly and Co's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(271.69-911.06)/271.69
=-235.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

Eli Lilly and Co Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Margin of Safety % (DCF Earnings Based)
Comparable Companies
JNJ ABBV MRK AMGN PFE GILD BMY BIIB OGN AMRN OCSE:NOVO B XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN TSE:4519 LSE:GSK TSE:4568 SHSE:600276 TSE:4578
Traded in Other Exchanges
LLY:Mexico 1LLY:Italy LLY:Germany LLYCL:Chile LLY:Switzerland LLY:Canada LILY34:Brazil LLY:Bulgaria LLYC:Austria LLY:Argentina
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Website
https://www.lilly.com
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Daniel Skovronsky officer: SVP, CSO, and Pres. LRL LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Johna Norton officer: Senior VP, Global Quality LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005